Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Go back to Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Delayed: 2.73 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.73 | 52 Week High | $8.30 | |||
| Open | $2.73 | 52 Week Low | $2.43 | |||
| Day High | $2.73 | P/E | N/A | |||
| Day Low | $2.73 | EPS | $-0.22 | |||
| Volume | 2,289 | |||||
